23andMe Holding Co., a prominent player in the personal genomics industry, has filed for Chapter 11 bankruptcy. The move is intended to facilitate a sale of the company’s business and address approximately $214 million in debt.
Simultaneously, Danimer Scientific Inc., a company specializing in the production of sustainable plastics alternatives, has also entered Chapter 11. Danimer’s filing indicates plans to wind down its operations and restructure its finances. These separate filings reflect the challenging economic climate and the pressures facing companies in various sectors.
